Real-world use of the EkoSonic system for sudden lung blood clots in China
Collects everyday care results of the EkoSonic device in Chinese adults with acute pulmonary embolism.
Key facts
- Who runs it
- Boston Scientific Corporation
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- A Real-World Study of EkoSonic Endovascular System in Chinese Populations With Acute Pulmonary Embolism
- Status
- Recruiting
- People taking part
- 30 people, planned
- Started
- 30 Sept 2026
- Expected to end
- 30 May 2029
- Type of study
- Observational
- Treatments tested
- EkoSonicTM Endovascular System
- Record updated
- 26 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in China with a sudden blood clot in the lungs (acute pulmonary embolism) whose doctor chose treatment with the EkoSonicTM Endovascular System and r-tPA. It collects real-world results from routine care.
- Age
- 18 Years and older
- Sex
- All sexes can join
- Disease stage
- Acute pulmonary embolism with symptoms that started less than 14 days ago. On a heart ultrasound, the right lower heart chamber must be as wide as or wider than the left one (ratio ≥1).
- Earlier treatment
- The doctor must have already chosen to treat the patient with the EkoSonicTM Endovascular System with r-tPA.
- Biomarker or test result
- Heart ultrasound (echocardiography) showing a right-to-left ventricle size ratio of ≥1.
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- The patients with acute symptomatic pulmonary embolism (Symptomatic duration < 14 days)
- The right ventricle diameter to left ventricle diameter of end-diastolic dimension ratio ≥1 measured by echocardiographic image
- Investigator has selected the EkoSonicTM Endovascular System with r-tPA to treat patient
Who cannot take part
- The patients with acute symptomatic pulmonary embolism (Symptomatic duration < 14 days)
- The right ventricle diameter to left ventricle diameter of end-diastolic dimension ratio ≥1 measured by echocardiographic image
- Investigator has selected the EkoSonicTM Endovascular System with r-tPA to treat patient
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study to collect the real-world clinical outcome data of EkoSonicTM Endovascular System in Chinese patients with acute pulmonary embolism during practical clinical care.
The group in the trial
- Single group observational study
To collect the real-world clinical outcome data of EkoSonicTM Endovascular System in Chinese patients with acute pulmonary embolism during practical clinical care.
Treatment: EkoSonicTM Endovascular System
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- EkoSonic Endovascular System in China RWS(ANTEATER)
- Plain-language title
- Real-world use of the EkoSonic system for sudden lung blood clots in ChinaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 26 October 2026